Survodutide

# Survodutide (Code Name: BI 456906)

> ⚠️ Important Notice: This compound is in the clinical trial phase and has not yet been approved for marketing by the FDA, EMA, or NMPA. It is for research use only. Promoting medical benefits such as weight loss or blood sugar reduction is strictly prohibited, and it must not be used for human treatment.
## Basic Chemical Information

– Product Name: Survodutide
– Development Code: BI 456906
– CAS Number: 2758740-55-5
– Category: GLP-1R / GCGR dual receptor agonist (GLP-1 + glucagon receptor dual agonist)
– Developer: Boehringer Ingelheim
– Amino Acids: 30-amino acid peptide, modified with fatty acid side chains, C-terminally amidated
– Molecular Formula: \(\boldsymbol{C_{186}H_{285}N_{47}O_{59}}\)
– Molecular weight: 4080.47 Da
– Appearance: White to off-white lyophilized powder
– Solubility: Easily soluble in dilute acetic acid; good water solubility
– Storage: Lyophilized powder: -20°C, sealed and protected from light; after reconstitution, may be stored at 2–8°C for up to 7 days
– Shelf life: 24 months (when stored properly)
– Administration: Once-weekly subcutaneous injection

## Mechanism of Action (Scientific / Clinical Mechanism)

1. GLP-1 receptor agonism: Glucose-dependent promotion of insulin secretion, inhibition of glucagon, delayed gastric emptying, reduced appetite, and decreased food intake
2. GCGR (glucagon receptor agonism): Enhances lipolysis, increases energy expenditure, reduces visceral fat, and improves hepatic lipid metabolism

>
> The synergistic dual-target approach simultaneously achieves glycemic control and weight loss; non-alcoholic fatty liver disease (NAFLD/NASH) is also a key area of research.

## Clinical Research Focus (Clinical trial data only; not a guarantee of efficacy)

– Overweight/Obesity: Phase II clinical trials demonstrated dose-dependent weight loss; the high-dose group showed particularly pronounced weight loss effects
– Type 2 Diabetes: Reduces blood glucose levels while significantly reducing body weight and improving metabolic markers
– NASH (Non-Alcoholic Steatohepatitis): A key area for expanding indications, evaluating improvements in hepatic fat, inflammation, and fibrosis
– Common Adverse Reactions: Gastrointestinal reactions (nausea, diarrhea, vomiting, constipation), mostly mild to moderate in severity, gradually resolving with dose titration

## Regulatory Status

– FDA / EMA / NMPA: Not yet approved for marketing; still in the clinical development phase
For research use only; claims of any therapeutic efficacy are prohibited